Galderma Group AG
GALD
Rangering i aksjer
#457
Galderma Group AG operates as a dermatology company worldwide. The company... Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
Aksjekurs
$224.81
Markedsverdi
$52.42B
Endring (1 dag)
6.31%
Endring (1 år)
31.28%
Land
CH
Handel Galderma Group AG (GALD)
Kategori
Healthcare
P/B-forhold for Galderma Group AG (GALD)
P/B-forhold per October 2026 TTM: 6.35
Ifølge Galderma Group AG sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 6.35. Ved slutten av 2024 hadde selskapet et P/B-forhold på 3.07.
P/B-historikk for Galderma Group AG fra 2021 til 2026
P/B-forhold ved hvert års slutt
| År | P/B-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 6.35 | 6.85% |
| 2025 | 5.94 | 93.64% |
| 2024 | 3.07 | 10.06% |
| 2023 | 2.79 | -8.45% |
| 2022 | 3.05 | 0.24% |
| 2021 | 3.04 | 0.00% |
P/B-forhold for lignende selskaper eller konkurrenter
| Selskap | P/B-forhold | Forskjell i P/B-forhold | Land |
|---|---|---|---|
| 1.9834 | -68.75% |
DE
|
|
| 2.1139 | -66.69% |
DE
|
|
| 1.3124 | -79.32% |
JP
|
|
| 5.0287 | -20.77% |
IN
|
|
| 4.7098 | -25.79% |
CN
|
